L. Jarrett Barnhill

Risperidone and explosive aggressive autism

Many autistic patients with mental retardation have difficulties with explosivity and aggression. They often prove resistant to various pharmacotherapeutic interventions. In this study, 11 male outpatients (mean 18.3 years) were administered risperidone in an open-label fashion. The risperidone was started at 0.5 mg daily, and titrated upwards until maximum clinical benefit occurred. Serial clinical interviews were conducted, and Conners Parent-Teacher Questionnaires (short form) were completed by the caretakers. Substantial clinical improvement was noted almost immediately in each patient, with aggression, self-injury, explosivity, and poor sleep hygiene most improved. The modal dose for optimal response was 0.5 mg bid. Weight gain was a significant side effect (average velocity of 0.47 kg per week), while none of the patients experienced extrapyramidal side effects.

Guanfacine and secondary mania in children

INTRODUCTION Guanfacine hydrochloride is an alpha-2 adrenergic agonist, which has gained recent attention in the field of child and adolescent psychiatry. This medication has been described as effective in the management of attention-deficit hyperactivity and tic disorders, with minimal side effects. METHODS Presented here are five cases of behavioral activation in children treated with guanfacine. RESULTS In each instance the clinical presentation resembled an acute hypomanic or manic episode. The dose of guanfacine was 0.5 mg/day. Later investigation revealed that all of the youngsters had clear risk factors (clinical and/or familial) for bipolar disorder. CONCLUSIONS It appears as though guanfacine may be capable of precipitating secondary mania in vulnerable children.

Treatment Models for Treating Patients with Combined Mental Illness and Developmental Disability

The presence of co-occurring psychiatric disorders among individuals with developmental disability (DD) requires clinicians to adjust and modify standard mental health assessment and treatment planning. In particular, assessment includes input from a multi-disciplinary team and as a result, diagnosis is frequently a synthesis of data from many different points of view. Treatment planning and implementation commonly include a collection of highly specialized, individualized programs that focus on the long term management of both disorders. Crises and recurrence of mental disorders are commonplace in part due to the presence of ongoing risk and vulnerability factors for mental disorders. As a result, the need for emergency interventions, specialized respite services, hospitalization and other transition services is extensive. The quality, availability and access to these services vary considerably. Many programs are concentrated in metropolitan or university-based centers and pose hardships based on geographic distance. The availability and utilization of services is affected by political, economic, socio-cultural and psychological forces that impact both the willingness to use services and the distribution of professionals trained and qualified to manage individuals with dual diagnoses. The complex interaction between each of these factors determines the structure, function, and capacity for innovation built into current service models.

Minimally effective doses of conventional antipsychotic medications used to treat aggression, self-injurious and destructive behaviors in mentally retarded adults.

Abstract: Retrospective review of records from 1990 to 1997 revealed unsuccessful attempts to withdraw antipsychotic medications from a total of 34 intellectually disabled individuals. The lowest dose of antipsychotic medication necessary to maintain symptom suppression and the dose at which relapse occurred were noted. Target behaviors observed indicating relapse included increased self-injurious behavior, aggression, and destructive/disruptive behaviors. Nineteen subjects received a low potency antipsychotic agent (ie, thioridazine or chlorpromazine) and 15 received a high potency antipsychotic agent (ie, haloperidol, loxapine, thiothixene). The mean lowest effective dose of chlorpromazine/thioridazine was 149.3 mg/d and relapse occurred at a mean dose of 93.6 mg/d. The mean lowest effective dose of haloperidol or related high potency drugs (expressed as haloperidol equivalents) was 5.9 mg/d, and relapse occurred at a mean dose of 3.8 mg/d.

The Diagnosis and Treatment of Individuals with Mental Illness and Developmental Disabilities : An Overview

Background The assessment and treatment psychiatric disorders among individuals with developmental disorders is in a state of flux. Clinicians working in this field confront two heterogeneous conditions based on separate but overlapping biopsychosocial bodies of scientific and clinical experiences. Methods The paper is a review of the relevant literature and an effort to synthesize sokme of the major problem areas in differential diagnosis and treatment planning. Results There are many genetic, metabolic and neurobehavioral factors that influence both challenging behaviors and the emergence, recognition, and clinical course of mental disorders in people with developmental disorders. As such, clinicians need to redefine dichotomous thinking about boundaries between psychiatrics, neurologic, and behavioral disorders and therapies. Discussion Even though there are efforts to adapt our various systems of nomenclature for individuals with developmental disorders, most still rely on descriptive and categorical models. It may be time to reconsider models that incorporate etiological factors in the process of differential diagnosis and classification. By doing so, clinicians may enhance their capacity to match individuals with more finely tuned treatment plans.

Antipsychotic withdrawal-induced relapse predicts future relapses in institutionalized adults with severe intellectual disability.

Severe intellectual and developmental disabilities are frequently associated with aggression toward self and others, destruction of property, and disruption. Antipsychotic medications are a mainstay of treatment of such behaviors. National and state guidelines suggest stopping these medications or decreasing their dosages when possible if patients have maintained stability. The current study evaluated the likelihood of future antipsychotic drug withdrawal-induced relapses in those individuals where such a relapse had occurred previously. Subjects were 57 institutionalized adults with severe or profound intellectual disability. Between 1990 and 2000, each had experienced an initial activation of maladaptive aggressive behaviors after an attempt at antipsychotic drug withdrawal and/or termination. Quarterly behavioral reports were evaluated to determine whether subsequent antipsychotic drug withdrawal attempts were also associated with future relapses. Initial relapse was followed by subsequent antipsychotic drug withdrawal attempts in 49 of the 57 individuals. Between 1990 and 2005, 28.6% of these 49 subjects had experienced 1, 38.7% had 2, 20.4% had 3, and 8.2% had 4 additional relapses. Two (4.1%) had not relapsed. Eight individuals remained on antipsychotic agents without a subsequent withdrawal attempt. By the end of 2005, only 4 (7%) of the 57 individuals had become antipsychotic drug free, 22.8% were receiving first-generation antipsychotic agents alone, 45.6% were receiving second-generation antipsychotic agents alone, and 24.6% were receiving a combination of first- and second-generation antipsychotic agents. Thus, if relapse occurs after an antipsychotic drug withdrawal attempt, subsequent attempts at withdrawal are also very likely to lead to further relapses.

Exploring Perspectives of Individuals with Intellectual Disabilities and Histories of Challenging Behaviors about Family Relationships: An Emergent Topic in a Grounded Theory Focus Group Study

ABSTRACT The perspectives of individuals with intellectual disabilities (ID) about family relationships are underrepresented in the literature. The topic of family relationships emerged in a grounded theory exploratory focus group study that involved thirty dually diagnosed participants with moderate or mild intellectual disabilities and histories of challenging behaviors. Because of the dearth of existing information and the salience of the topic, this analysis explored properties of the participant’s disclosures associated with family relationships. The aims were to offer treatment providers empirically based information that may inform service provision and increase the availability of ID-specific, psychological supports for dually diagnosed individuals. Participants reported different types and statuses of family relationships. Transactional processes described in positive family relationships included properties such as reciprocity, flexibility, accommodation, trusting, and expressing affection. Conversely, participants described transactional relationship barriers (e.g., victimizing, behavioral dys-control, and substance abuse) that involved dysregulated behaviors of both the participants and family members in conflicted and severed family relationships. These factors appeared to lead to co-dysregulation versus co-regulation within the family relationships. These findings are relevant given the consensus in the literature that environmental factors are associated with challenging behaviors. Not only do treatment providers need to understand potential family relationship patterns to provide individual supports, but these multilayered factors may warrant seeking additional treatment modalities that address emotion regulation deficits of the participants and family members, trauma-informed treatment, and family therapy. Additionally, conceptualizing family relationships as transactional may help families and collateral supports co-construct positive, collaborative transactions with dually diagnosed individuals that improve the quality of life of all involved.